It is postulated that the unstable hydroxylamine metabolite of sulphamethoxazole is responsible for the adverse reactions to co-trimoxazole and in HIV infection systemic glutathione deficiency leads to a reduced capacity to counteract the hydroxylamine toxicity. This hypothesis has been investigated by studying the metabolism of sulphamethoxazole and assessing glutathione status in HIV infection in order to explore the modification of treatment. It is concluded that the toxicity of plasma sulphamethoxazole hydroxylamine is counteracted by normal glutathione concen trations as is the case in HIV-seropositive patients, but that increased oxidation within certain cells in HIV infected individuals may possibly give rise to increased concentrations of reactive intermediates of sulphamethoxazole.
Introduction
The com bination o f trimethoprim and sulphamethoxazole (co-trimoxazole) is an im portant drug for the treatment and primary and secondary prophylaxis of Pneumocystis carinii pneum onia (PCP) in patients with infection caused by the hum an immunodeficiency virus (H IV ). However, the administration o f co-trimoxazole in these patients is often hampered because the frequency o f adverse reactions to this drug in H IV infected patients is much higher compared with seronegative individuals (Kovacs et a l 1984) . These side-effects, which are often labeled as 'allergic', consist o f rash, fever and damage to liver parenchymal cells. A lthough H IV seropositive individuals are more susceptible to side-effects similar to those associated with a number of other, unrelated drugs (reviewed by C oopm an et a l., 1993; K oopm ans et a l., 1995) , this review focuses on the side-effects o f co-trimoxazole. 
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Some years ago, we hypothesized that this increased frequency o f toxicity to co-trimoxazole is caused by a com bination o f two factors (van der Ven et a l., 1991, 19946) . First of all, the hydroxylamine derivative o f sulphamethoxazole is an unstable metabolite that can undergo auto-oxidation to become a protein-reactive nitroso derivative, and this substance could be responsible for the adverse reactions to co-trimoxazole (Shear et a l., 1986; Rieder et a l., 1988 Rieder et a l., , 1989 . This means that the sulphonamide component of co-trimoxazole is largely responsible for the side-effects, although the oxidation of trimethoprim could possibly also lead to hydroxylamine formation. Secondly, H IV infected individuals have a systemic glutathione deficiency (Buhl et a l., 1989; Eck et a l., 1989) . This deficiency implies that there is a reduced capacity to prevent auto-oxidation o f the unstable sulphonamide intermediates, and to scavenge reactive compounds. As a consequence, there is an increased exposure o f cells to toxic intermediates and this could lead to the adverse reactions.
The hypothesis was the subject o f a series o f investigations carried out by our group. The investigations comprised studies o f the metabolism o f sulphamethoxazole and other sulphonamides, the assessment o f the glutathione status in HIV-infected patients and the exploration o f treatment modifications.
Sulphamethoxazole metabolism
Sulphamethoxazole is extensively metabolized in vivo; its metabolic pathways involve acetylation, oxidation and glucuronidation (Vree & Mekster, 1987; Vree et a l., 1994) .
Oxidation takes place at different positions o f the molecule: the unstable, reactive hydroxylamine metabolite is formed by oxidation o f the N 4 nitrogen atom while oxidation o f the C5 methyl group leads to the stable 5-hydroxy metabolite. Form ation o f both metabolites by cytochrome P450-mediated reaction was demonstrated in vitro using hum an liver microsomes. In vitro more sulphamethoxazole was N-hydroxylated than 5-hydroxylated (van der Ven et a l 1995a).
The pharmacokinetics o f sulphamethoxazole and its metabolites were reported in healthy volunteers after a single dose (Vree et a l., 1994 (Vree et a l., , 1995 . The patterns o f the form ation and elim ination o f sulphamethoxazole hydroxylamine were similar to the other metabolic products, and the renal excretion o f sulphamethoxazole hydroxylamine accounted for 2-4% o f the recovered dose (van der Ven et a l., 1994c). The mean residence time o f the hydroxylamine metabolite was 5-5 h; the renal clearance amounted 4-39 L/h. Thus, under physiological conditions most sulphamethoxazole hydroxylamine seems to be stable, escapes the liver and is excreted by the kidney.
Next, the pharmacokinetics o f sulphamethoxazole and its metabolites were also investigated in HIV-seropositive individuals after a single oral dose (van der Ven et a l., 19956) . Sulphamethoxazole hydroxylamine is the only com pound for which the urinary recovery was found to be different from healthy volunteers. The impaired recovery o f sulphamethoxazole hydroxylamine in HIV-seropostive patients (50% reduction) may be explained by secondary metabolism to the protein reactive nitroso derivatives. A t the time o f the investigations, it was not clear whether this auto-oxidation occurred in the urine ex vivo or in vivo because of glutathione deficiency. Because the urinary excretion o f all other metabolites o f sulphamethoxazole, including 5-hydroxy sulphamethoxazole and N4-acetyl-5-hydroxy-sulphamethoxazole, was similar between HIV-seropositive 57 individuals and healthy controls, we concluded that there was no difference in oxidation, acetylation and glucuronidation (van der Ven et a l., 19946) . Taken together, we conclude that sulphamethoxazole hydroxylamine is indeed being formed during treatment with sulphamethoxazole by both normal individuals and HIV-seropositive patients.
A lthough the cytotoxic potential o f hydroxylamines o f sulphonamides can be demonstrated in vitro (Rieder et a l., 1988 (Rieder et a l., , 1989 , the relative toxicity o f these compounds, as compared with the parent com pounds (which also exert cytotoxicity; A. J. A. M . van der Ven, unpublished observations), has not been assessed in terms o f the relative concentrations in vivo.
Glutathione status G lutathione is the m ain intracellular defense against oxidative stress and is o f m ajor importance for xenobiotic metabolism. Intracellular concentrations o f glutathione are high, while plasma concentrations are low. Several groups have reported decreased glutathione concentrations in H IV infection, in particular in plasma, broncho-alveolar lavage, peripheral blood mononuclear cells (Buhl et a l., 1989; Eck et a l., 1989) , and also in C D 4 + and C D 8 + T lymphocytes (Roederer et a l., 1991) . Based on these investigations, it was concluded that H IV infection is associated with a systemic glutathione deficiency. G lutathione concentrations in C D 4 + and C D 8 + T lymphocytes were determined using m onochlorobim ane as a fluorescent label. However, when we evaluated this method, we found that many variables influenced the cellular fluorescence, including the presence o f alternative metabolic pathways for m onochlorobim ane and the rapid excretion of glutathione-bimane conjugate out o f the cell. We concluded that this label cannot be used to assess glutathione levels in these cells (van der Ven et a l., 1994<r/).
High performance liquid chromatography is a validated method to measure glutathione concentrations and was employed to measure free and protein-bound glutathione concentrations in HIV-seropositive individuals and healthy controls. Both forms o f glutathione were determined because free glutathione is im portant for the maintenance o f thiol redox status, while increased concentrations of protein-bound glutathione indicate oxidative stress. We found that free intracellular glutathione concentrations in erythrocytes, C D 14 cells and C D 4 cells were not different between HIV-seropositive individuals and healthy controls (A. J. A. M . van der Ven, H. Blom, W . H. M . Peters. L. E. H. Jacobs, I. J. O. Verver, P. P. K oopm ans, P. Demacker & J. W . M . van der Meer, unpublished observations). In addition, we found that plasma concentrations o f free glutathione were also not different. Based on these findings, we concluded that H IV infection is not associated with a systemic glutathione deficiency. It was found, however, that the protein-bound form o f glutathione was increased, particularly in C D 4 cells o f H IV seropositive subjects which strongly suggests the presence o f increased oxidative stress.
So far, we have concluded that the toxicity o f sulphamethoxazole hydroxylamine in plasma is counteracted by norm al glutathione concentrations, not only in norm al controls but also in HIV-seropositive patients. It could be speculated that in these patients, the presence o f increased oxidation within certain cells may lead to increased concentrations o f reactive intermediates o f sulphamethoxazole. It is clear that further research is needed in this area. 
Treatment modification
Treatment modification with regard to the choice of the sulphonamides was also investigated. We explored the metabolism of a number of different sulphonamides to try and select a sulphonamide that would generate less hydroxylamine. Ten different sulphonamides were incubated in vitro with hum an liver microsomes. These experiments indicated that all sulphonamides tested generated stable as well as unstable oxidised metabolites, but not all to the same extent. The generation of oxidised products was least for sulphametrole. In vivo the rate o f oxidation between the various sulphonamides also differs; the same holds true for the rate o f acetylation and glucuronidation (Vree & Hekster, 1987) . It is generally accepted that the acetylated com pound is non-toxic (Rieder et al., 1991) ; thus, a sulphonamide that is accessible for acetylation but not for oxidation may be more favourable than an extensively metabolized com pound like sulphamethoxazole. The acetylation of sulphametrole in vivo has been previously reported (Hekster et al., 1981) , and to date is the only metabolic reaction.
Re-examination of sulphametrole metabolism using mass spectrometry did not indicate the presence of any oxidised metabolite in the urine o f healthy controls and H IV seropositives (W . Welz, personal com m unication). Since a stable hydroxy metabolite could not be detected, it is likely that sulphametrole is not accessible for cytochrome P450 mediated reactions in vivo. Like sulphamethoxazole, sulphametrole is commercially available in a 5:1 dose ratio with trimethoprim (Co-soltrim). Sulphamethoxazole and sulphametrole have similar half-lifes (10 h).
From the inability to detect hydroxylamine metabolites o f sulphametrole, we were eager to know whether adm inistration o f sulphametrole would meet with fewer adverse effects, especially in H IV seropositive patients. This was supported by a report in the literature, in which sulphametrole did not appear to be associated with haemolysis when administered in a population with a high prevalence o f glucose-6-phosphate dehydrogenase deficiency (Plummer et a l., 1983) . These patients lack the capacity to keep glutathione in its reduced form, especially in the red blood cells; sulphamethoxazole is known to cause haemolysis in these patients (Beutler, 1991) . Recently, we performed a retrospective analysis o f 58 H IV infected patients treated for PCP with Co-soltrim in two centres. The analysis showed that only skin reactions or fever were indications to alter medication and that adverse reactions occurred less frequently than has been reported previously for co-trimoxazole (A. J. A. M . van der Ven, A. Rieger, A. Brahten, R. Reim an, T. B. Vree, P. P. Koopm ans, J. W . M . van der Meer, personal observations). These results would justify a prospective controlled study comparing the frequency o f side-effects o f sulphamethoxazole and sulphametrole in HIV-infected patients.
Since our hypothesis points to a concentration-dependent mechanism rather than to an allergic (i.e., concentration-independent) mechanism, dose reduction would be an option. Such a strategy finds some support from the study o f Schneider et al. (1992) , which demonstrated that a relatively low dosage of co-trimoxazole (480 mg daily) for PCP prophylaxis in HIV-positive patients was associated with delayed occurrence of side-effects than a higher dosage (960 mg daily). In view o f this dosage dependency, we investigated the optim al dosage ratio o f sulphonamide and dihydrofolate reductase (D H F R ) inhibitors (trimethoprim and pyrimethamine). A t present the achieved plasma concentration o f the sulphamethoxazole (100-200 mg/L) is much higher than that of the D H F R inhibitor (for trimethoprim 5-10 g/L). The dosage recommendations are based on inhibitory concentrations of each com pound separately w ithout taking into account the synergic effect o f the com bination. This synergic effect was demonstrated in an in-vitro study using Toxoplasma gondii. W e found that the 50% inhibitory concentration o f sulphamethoxazole reduced from 500 to 0.05 g/L when pyrimethamine 0.05 g/L was added to the medium; the plasma concentrations o f pyrimethamine obtained with a once weekly dose of 75 mg are around 0.2 g/L (A. J. M . van der Ven, E. M . E. Schoondermark van de Ven, W . Camps, W . J. G . Melchers, P. P. K oopm ans, J. W . M . van der Meer & J. M . D . G alam a, personal observations). These findings could imply that the present dosage recommendations for sulphonamides, when combined with trimethoprim or pyrimethamine, are too high, and thereby result in unnecessary increased toxicity. Reduction o f the toxicity o f the current first line treatments for P. carinii and T. gondii by selection o f a less toxic sulphonamide used with a D H F R inhibitor at an adjusted dosage ratio should be investigated.
